Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: HELIX BIOPHARMA (HBP:TSE)

No earlier versions found for this Subject.

Return to HELIX BIOPHARMA (HBP:TSE)

This company has recently undergone a merger, acquired a TSE listing, enhanced its product line with generic pharmaceuticals under licence with Bausch & Lomb and Copley, and is working on a new approach to develop an anti-infective technology. Excellent management that has grown the company from scratch.
They are also the only privately licenced DNA lab in Canada and hold exclusive rights to patented DNA identity testing. Much of this is geared toward Immigration and Paternity cases.